A longitudinal model for magnetic resonance imaging lesion count data in multiple sclerosis patients

Statistics in Medicine

Volumn 31, Issue 5, 2012, Pages 449-469

  Mackay Altman, Rachel ^a   Petkau, A John ^b   Vrecko, Dean ^b   Smith, Alex ^c  

^a SIMON FRASER UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Cerexa Inc   (United States)

Author keywords

Clinical trials; Hypothesis testing; Latent variables; Longitudinal count data; Mixed hidden Markov model; Model diagnostics

Indexed keywords

ARTICLE; HIDDEN MARKOV MODEL; HUMAN; LIKELIHOOD RATIO TEST; MULTIPLE SCLEROSIS; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; RANK SUM TEST; RELAPSE; REMISSION; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; VARIANCE;

ANALYSIS OF VARIANCE; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; LIKELIHOOD FUNCTIONS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MARKOV CHAINS; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS, NONPARAMETRIC;

EID: 84856427626     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4394     Document Type: Article

References (27)

1. Young IR, Hall AS, Pallis CA, Legg NJ, Bydder GM, Steiner RE. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2:1063-1066.
2. Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF, Wolinsky JS. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Multiple Sclerosis 2008; 14:770-778.
3. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72:705-711.
4. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Annals of Neurology 2009; 65:268-275.
5. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic-resonance-imaging in monitoring the treatment of multiple-sclerosis patients-statistical power of parallel-groups and crossover designs. Journal of the Neurological Sciences 1994; 122:6-14.
6. Truyen L, Barkhof F, Tas M, Van Walderveen MAA, Frequin STFM, Hommes OR, Nauta JJP, Polman CH, Valk J. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. Multiple Sclerosis 1997; 2:283-290.
7. Tubridy N, Ader HJ, Barkhof F, Thompson AJ, Miller DH. Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. Journal of Neurology, Neurosurgery, and Psychiatry 1998; 64:50-55.
8. Smith A. Design strategies for repeated MRI scanning in multiple sclerosis clinical trials. Unpublished MSc Thesis, University of British Columbia, Department of Statistics, 1999.
9. Sormani MP, Miller DH, Comi G, Barkhof F, Rovaris M, Bruzzi P, Filippi M. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. Journal of Neurology, Neurosurgery, and Psychiatry 2001; 70:494-499.
10. Aban IB, Cutter GR, Mavinga N. Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data. Computational Statistics and Data Analysis 2009; 53:820-833.
11. Sormani MP, Bruzzi P, Miller DH, Gasperini C, Barkhof F, Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. Journal of the Neurological Sciences 1999; 163:74-80.
12. Sormani MP, Bruzzi P, Rovaris M, Barkhof F, Comi G, Miller DH, Cutter GR, Filippi M. Modelling new enhancing MRI lesion counts in multiple sclerosis. Multiple Sclerosis 2001; 7:298-304.
13. van den Elskamp IJ, Knol DL, Uitdehaag BMJ, Barkhof F. The distribution of new enhancing lesion counts in multiple sclerosis: further explorations. Multiple Sclerosis 2009; 15:42-49.
14. Albert PS, McFarland HF, Smith ME, Frank JA. Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. Statistics in Medicine 1994; 13:453-466.
15. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Annals of Neurology 1992; 32:758-766.
16. Altman RM, Petkau AJ. Application of hidden Markov models to multiple sclerosis lesion count data. Statistics in Medicine 2005; 24:2335-2344.
17. Li X. Stochastic models for MRI lesion count sequences from patients with relapsing remitting multiple sclerosis. Unpublished PhD Thesis, The Ohio State University, Department of Statistics, 2006.
18. Healy BC, Ikle D, Macklin EA, Cutter G. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. Multiple Sclerosis 2010; 16:840-847.
19. Altman RM. Mixed hidden Markov models: an extension of the hidden Markov model to the longitudinal data setting. Journal of the American Statistical Association 2007; 102:201-210.
20. Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 2008; 70:1092-1097.
21. Vrecko D. Efficient designs of multiple sclerosis clinical trials. Unpublished MSc Thesis, Simon Fraser University, Department of Statistics and Actuarial Science, 2007.
22. Sormani MP, Bruzzi P, Comi G, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002; 58:417-421.
23. MacKay RJ. Estimating the order of a hidden Markov model. The Canadian Journal of Statistics 2002; 30:573-589.
24. Altman RM. Assessing the goodness-of-fit of hidden Markov models. Biometrics 2004; 60:444-450.
25. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bulletin of the International Statistical Institute 1960; 37:351-361.
26. Bajorski P, Petkau J. Nonparametric two-sample comparisons of changes on ordinal responses. Journal of the American Statistical Association 1999; 94:970-978.
27. Borm GF, Fransen J, Lemmens WAJG. A simple sample size formula for analysis of covariance in randomized clinical trials. Journal of Clinical Epidemiology 2007; 60:1234-1238.